YolTech Therapeutics, founded in 2021 and based in Shanghai, develops next-generation in vivo gene-editing therapies designed as one-time treatments. Its integrated platform includes proprietary CRISPR nucleases (YolCas), base editors (YolBE), and a lipid nanoparticle delivery system (Yol-LNPs) for tissue-specific editing. The company has advanced four clinical-stage programs addressing ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD), and its lead program YOLT-201 entered Phase I/IIa in China in 2024. Its base-editing therapy YOLT-101 received IND clearance in both China and the United States. YolTech operates a cGMP-compliant manufacturing facility supporting clinical supply through Phase III and early commercial scale-up to ensure consistency and scalability. The company intends to use financing proceeds to advance its clinical programs and support global strategic execution. 尧唐生物 is a global leader in in‑vivo gene editing and base editing that owns foundational patents for CRISPR/Cas and single‑base deaminase tools. The company maintains three proprietary technology platforms—Cas enzymes, base editors, and lipid nanoparticle (LNP) delivery—with independent IP and core patent protection for global implementation. It has assembled international experts in gene‑editing tool discovery, mRNA‑LNP process development, and CMC to accelerate mRNA‑LNP‑mediated in‑vivo gene‑editing therapeutics and clinical translation. The lead program, YOLT‑201, has completed toxicology and pharmacology studies and shown preliminary safety and efficacy in large‑animal studies, delivering best‑in‑class single‑dose in‑vivo editing efficiency. The company has submitted an IND for YOLT‑201 to China’s NMPA and aims to open a registration clinical trial for an mRNA‑LNP delivered in‑vivo gene‑editing therapy. Financially,尧唐生物 has raised nearly RMB 300 million across its A‑series and recently closed an A+ round of over RMB 100 million to accelerate clinical development and global pipeline expansion.

Total raised

$59M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2025